Moreover, defactinib (VS-6063), a FAK and proline-rich tyrosine kinase 2 (PYK2) dual inhibitor, is currently undergoing multiple clinical trials in NSCLC and mesothelioma (16). This evidence concerns the gene PTK2B and non-small cell lung carcinoma.